Cargando…
MLL3 is a de novo cause of endocrine therapy resistance
BACKGROUND: Cancer resequencing studies have revealed epigenetic enzymes as common targets for recurrent mutations. The monomethyltransferase MLL3 is among the most recurrently mutated enzymes in ER+ breast cancer. The H3K4me1 marks created by MLL3 can define enhancers. In ER+ breast cancer, ERα gen...
Autores principales: | Stauffer, Kimberly M., Elion, David L., Cook, Rebecca S., Stricker, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559462/ https://www.ncbi.nlm.nih.gov/pubmed/34581028 http://dx.doi.org/10.1002/cam4.4285 |
Ejemplares similares
-
MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer
por: Zhu, Changyu, et al.
Publicado: (2023) -
Interaction between MLL3 genetic polymorphisms, smoking, and alcohol drinking in laryngeal cancer: a case–control study
por: Chen, Dong, et al.
Publicado: (2016) -
Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia
por: Richter, William F, et al.
Publicado: (2021) -
Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
por: Shan, Xiaochuan, et al.
Publicado: (2017) -
HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis
por: Takahashi, Satoshi, et al.
Publicado: (2021)